Can hyperlipidemia be protective to the brain? the paradox of lowering lipid levels in cerebrovascular disease

Clinical Lipidology

Volumn 5, Issue 3, 2010, Pages 295-298

  Rost, Natalia S ^a   Rosand, Jonathan ^a   Woo, Daniel ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PROTECTION; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 77953860871     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.31     Document Type: Editorial

References (54)

1. Schwamm L, Fayad P, Acker JE III et al.: Translating evidence into practice: a decade of efforts by the American Heart Association/American Stroke Association to reduce death and disability due to stroke. A Presidential advisory from the American Heart Association/American Stroke Association. Stroke 41(5), 1051-1065 (2010).
2. Towfighi A, Ovbiagele B, Saver JL: Therapeutic milestone: stroke declines from the second to the third leading organ- and disease-specific cause of death in the United States. Stroke 41, 499-503 (2010).
3. Brainin M, Teuschl Y, Kalra L: Acute treatment and long-term management of stroke in developing countries. Lancet Neurol. 6, 553 (2007).
4. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 22, 312-318 (1991).
5. Goldstein LB, Adams R, Alberts MJ et al.: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37, 1583-1633 (2006).
6. Rothwell PM, Coull AJ, Giles MF et al.: Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363(9425), 1925-1933 (2004).
7. Adams H, Adams R, Del Zoppo G, Goldstein LB: Guidelines for the early management of patients with ischemic stroke: 2005 Guidelines Update. A Scientific Statement From the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36, 916-923 (2005).
8. Schulz UG, Rothwell PM: Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 34, 2050-2059 (2003).
9. Amarenco P, Lavallée P, Touboul P-J: Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 3, 271 (2004).
10. Amarenco P, Steg PG: The paradox of cholesterol and stroke. Lancet 370, 1803 (2007).
11. Amarenco P, Bogousslavsky J, Callahan A III et al.; for the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels I. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559 (2006).
12. Adams RJ, Albers G, Alberts MJ et al.: Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39, 1647-1652 (2008).
13. Lewington S, Whitlock G, Clarke R et al.; for the Prospective Studies Collaboration: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 370, 1829-1839 (2007).
14. Broderick J, Connolly S, Feldmann E et al.: Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/ American Stroke Association Stroke Council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38, 2001-2023 (2007).
15. Greenberg SM: Small vessels, big problems. N. Engl. J. Med. 354, 1451-1453 (2006).
16. Rosand J, Greenberg SM: Beyond hypertension: unraveling the causes of intracerebral hemorrhage. Stroke 33, 1195-1196 (2002).
17. Rosand J: Hypertension and the brain: stroke is just the tip of the iceberg. Neurology 63, 6-7 (2004).
18. Segal AZ, Chiu RI, Eggleston-Sexton PM, Beiser A, Greenberg SM: Low cholesterol as a risk factor for primary intracerebral hemorrhage: a case-control study. Neuroepidemiology 18, 185-193 (1999).
19. Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S: Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? Stroke 27, 1993-1998 (1996).
20. Woo D, Kissela BM, Khoury JC et al.: Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 35, 1360-1364 (2004)
21. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
22. Collins R, Armitage J, Parish S, Sleight P, Peto R; for the Heart Protection Study Collaborative Group: Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363(9411), 757-767 (2004).
23. Bang OY, Saver JL, Liebeskind DS et al.: Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 68, 737-742 (2007).
24. Kim BJ, Lee S-H, Ryu W-S, Kang BS, Kim CK, Yoon B-W: Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism. Stroke 40, 1627-1632 (2009) .
25. Goldstein LB: Low LDL cholesterol, statins, and brain hemorrhage: should we worry? Neurology 68, 719-720 (2007).
26. Roquer J, Campello AR, Gomis M, Ois A, Munteis E, Bohm P: Serum lipid levels and in-hospital mortality in patients with intracerebral hemorrhage. Neurology 65, 1198-1202 (2005).
27. Ramirez-Moreno JM, Casado-Naranjo I, Portilla JC et al.: Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage. Stroke 40, 1917-1920 (2009).
28. Bjorkhem I, Meaney S: Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24, 806-815 (2004).
29. Chobanian AV, Hollander W: Body cholesterol metabolism in man. I: the equilibration of serum and tissue cholesterol. J. Clin. Invest. 41, 1732-1737 (1962).
30. Reese TS, Karnovsky MJ: Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34, 207-217 (1967).
31. Dehouck BND, Fenart L, Dehouck M-P, Pierce A, Torpier GR, Cecchelli RO: A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877-889 (1997).
32. Meaney S, Bodin K, Diczfalusy U, Bjorkhem I: On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J. Lipid Res. 43, 2130-2135 (2002).
33. Dietschy JM, Turley SD: Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12, 105-112 (2001).
34. Dehouck B, Dehouck MP, Fruchart JC, Cecchelli R: Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J. Cell Biol. 126, 465-473 (1994).
35. Rodriguez C, Slevin M, Rodriguez-Calvo R et al.: Modulation of endothelium and endothelial progenitor cell function by low-density lipoproteins: implication for vascular repair, angiogenesis and vasculogenesis. Pathobiology 76, 11-22 (2009).
36. Mauch DH, Nagler K, Schumacher S et al.: CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357 (2001).
37. Goritz C, Mauch DH, Pfrieger FW: Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol. Cell. Neurosci. 29, 190 (2005).
38. Chui D, Marotta F, Rao ML, Liu D, Zhang S, Ideo C: Cholesterol-rich LDL perfused at physiological LDL-cholesterol concentration induces platelet aggregation and PAF-acetylhydrolase activation. Biomed. Pharmacother. 45, 37-42 (1991).
39. Eryurek F, Surmen S, Oner P, Altug T, Oz H: g-glutamyl transpeptidase and acetylcholinesterase activities in brain capillaries of cholesterol-fed rabbits. Res. Commun. Chem. Pathol. Pharmacol. 69, 245-248 (1990).
40. Vatassery GT, Smith WE, Quach HT, Lai JCK: In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals. Neurochem. Intl 26, 527 (1995).
41. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology 56, 1539-1545 (2001). (Pubitemid 32532267)
42. Prins ND, van Dijk EJ, den Heijer T et al.: Cerebral white matter lesions and the risk of dementia. Arch. Neurol. 61, 1531-1534 (2004).
43. Longstreth WT, Manolio TA, Arnold A et al.: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke 27, 1274-1282 (1996).
44. Smith EE, Gurol ME, Eng JA et al.: White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 63, 1606-1612 (2004).
45. Ay H, Arsava EM, Rosand J et al.: Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke 39, 1409-1413 (2008).
46. Arsava EM, Rahman R, Rosand J et al.: Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke. Neurology 72, 1403-1410 (2009).
47. Rost NS, Rahman R, Sonni S et al.: Determinants of white matter hyperintensity volume in patients with acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 19(3), 230-235 (2010).
48. Jimenez-Conde J, Biffi A, Rahman R et al.: Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke 41, 437-442 (2010).
49. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30, 1969-1973 (1999).
50. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L: Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 13, 208-213 (2007).
51. Endres M, Laufs U: Effects of statins on endothelium and signaling mechanisms. Stroke 35, 2708-2711 (2004).
52. Buckley BM: Review: lipids and stroke. Brit. J. Diab. Vasc. Dis. 3, 170-176 (2003).
53. Di Napoli P, Taccardi AA, Oliver M, De Caterina R: Statins and stroke: evidence for cholesterol-independent effects. Eur. Heart J. 23, 1908-1921 (2002).
54. Goldstein LB, Suarez JI: The quest for the 'Holy Grail' of ischemic stroke cytoprotection: statins may not be the answer. Neurology 73, 2058-2059 (2009).